2023 World Conference on Lung Cancer (Posters)-EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study

EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study - PDF(Abstract)

Back to course

Pdf Summary

A real-world prospective study conducted at Central South University Xiangya Hospital evaluated the effects of combining neoadjuvant immunochemotherapy and probiotic supplements as a therapeutic strategy in non-small cell lung cancer (NSCLC). The study aimed to assess the potential benefits of this combined treatment on pathological response and progression-free survival (PFS). <br /><br />43 eligible patients with stage IIB to IIIB NSCLC received three cycles of nivolumab plus platinum-based chemotherapy along with daily oral administration of probiotic supplements containing Bifidobacterium, Lactobacillus acidophilus, and Enterococcus faecalis. After the neoadjuvant treatment, all 43 patients underwent tumor resection, with 23 patients (53.5%) achieving a pathological complete response (pCR). At 19 months of follow-up, the PFS was 93.0%.<br /><br />The study observed that the combined therapy resulted in a high pCR rate, a long PFS, and a low incidence of severe treatment-related adverse events (trAE). Out of the 43 patients, 97.7% experienced trAE, but only 14.0% had trAE of grade 3, and no adverse events were associated with surgery delays or deaths.<br /><br />Analysis of the patients' gut microbiota showed that the beta diversity index of gut microbiota increased after receiving neoadjuvant immunochemotherapy plus probiotic supplements. There were also significant variations in the microbiome structures at the species level between the pCR group and the non-pCR group.<br /><br />Based on the results, the study suggests that patients with stage IIB-IIIB NSCLC who received neoadjuvant immunochemotherapy plus probiotic supplements had positive outcomes. The involvement of gut microbiota in the response to neoadjuvant immunochemotherapy in NSCLC requires further investigation.<br /><br />In summary, combining neoadjuvant immunochemotherapy with probiotic supplements showed promising results in terms of pCR rate, PFS, and trAE in patients with stage IIB-IIIB NSCLC. The study highlights the potential role of gut microbiota in the response to neoadjuvant therapy in NSCLC, necessitating further research.

Asset Subtitle

Min Li

Meta Tag

Speaker Min Li

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

Central South University Xiangya Hospital

neoadjuvant immunochemotherapy

probiotic supplements

non-small cell lung cancer

NSCLC

pathological response

progression-free survival

nivolumab

platinum-based chemotherapy

gut microbiota